Autonomic Technologies Incorporated, a medical device manufacturer based in Redwood City, California, announced the results of a clinical trial for its ATI Neurostimulation System. According to a press release by the company, the multicenter European clinical trial demonstrated efficacy for the device in relieving pain caused by cluster headaches.
In its press release, the company detailed how the device works. The ATI Neurostimulation System comprises a small, implantable neurostimulator the size of an almond. This neurostimulator is designed to be activated by patients on an as-needed basis. Through a remote control (the same size as a smartphone), patients can achieve relief from the pain caused by cluster headaches. Once the headache has been treated, patients move the remote controller away from the cheek. This automatically turns off the ATI Neurostimulation System.
According to results from the clinical trial, the ATI Neurostimulation System (now available in Europe), helped patients achieve significant relief from cluster headaches. In addition to improving patient quality of life, the study showed that the SPG stimulation system may reduce the number of cluster headaches experienced by a patient.
Ben Pless is the CEO and president of Autonomic Technologies. In prepared remarks, he said, "We are very pleased with the positive results of the clinical study." He continued, "We are delighted to start making the ATI Neurostimulation System available to cluster headache patients in Europe so that they may control their painful attacks."